A multi-center double-blind, placebo-controlled randomized study of bicifadine 200 mg BID [twice-daily], bicifadine 300 mg BID, and bicifadine 400 mg BID in the treatment of chronic low back pain

Trial Profile

A multi-center double-blind, placebo-controlled randomized study of bicifadine 200 mg BID [twice-daily], bicifadine 300 mg BID, and bicifadine 400 mg BID in the treatment of chronic low back pain

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2006

At a glance

  • Drugs Bicifadine (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors Euthymics Bioscience
  • Most Recent Events

    • 21 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top